Lilly Profit Falls Short as Humalog Insulin Sales Disappoint

Lilly Profit Falls Short as Humalog Insulin Sales Disappoint


Eli Lilly & Co. posted third-quarter profit that missed analysts' predictions after disappointing sales from both its best-selling treatment, the blockbuster Humalog insulin, and newer products like diabetes pill Jardiance.



from Biotech News